ME3241
/ Meiji Seika
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 20, 2026
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ME3241 Administered Intravenously in Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=104 | Not yet recruiting | Sponsor: Meiji Pharma USA Inc.
First-in-human • New P1 trial
1 to 1
Of
1
Go to page
1